T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alcon
ALC
|
+$2.11B |
| 2 |
Linde
LIN
|
+$1.34B |
| 3 |
American International
AIG
|
+$1.34B |
| 4 |
Marvell Technology
MRVL
|
+$1.28B |
| 5 |
TSS
Total System Services, Inc.
TSS
|
+$1.24B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$2.27B |
| 2 |
Eli Lilly
LLY
|
+$1.64B |
| 3 |
NVIDIA
NVDA
|
+$1.59B |
| 4 |
RHT
Red Hat Inc
RHT
|
+$1.55B |
| 5 |
Booking.com
BKNG
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.88% |
| 2 | Healthcare | 16.96% |
| 3 | Financials | 13.79% |
| 4 | Consumer Discretionary | 13.57% |
| 5 | Industrials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HCCI
926
DELISTED
Heritage-Crystal Clean, Inc.
HCCI
| $44.7M | 0.01% |
1,698,218
+499
| +0% | +$13.3K |
|
927
T. Rowe Price
TROW
$23.8B
| $44.6M | 0.01% |
406,940
-1,727
| -0.4% | -$182K |
|
928
Manhattan Associates
MANH
$11.2B
| $44.4M | 0.01% |
640,807
-2,366
| -0.4% | -$152K |
|
|
GRFS
929
Grifois
GRFS
$5.4B
| $44.2M | 0.01% |
2,096,661
-2,540,837
| -55% | -$48.5M |
|
|
GTHX
930
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $43.7M | 0.01% |
1,424,609
-65,558
| -4% | -$1.38M |
|
931
Virtus Investment Partners
VRTS
$1.12B
| $43.6M | 0.01% |
406,120
-10,759
| -3% | -$1.2M |
|
932
Generac Holdings
GNRC
$13.1B
| $43.5M | 0.01% |
627,076
-7,367
| -1% | -$431K |
|
933
Kirby Corp
KEX
$7.18B
| $43.5M | 0.01% |
550,943
-4,956
| -0.9% | -$398K |
|
934
Adaptive Biotechnologies
ADPT
$4.02B
| $43.5M | 0.01% |
+900,000
| New | +$39.9M |
|
935
Hartford Financial Services
HIG
$37.7B
| $43.5M | 0.01% |
779,902
+89,832
| +13% | +$4.74M |
|
936
Fluor
FLR
$6.96B
| $43.3M | 0.01% |
1,284,676
+720,654
| +128% | +$24.1M |
|
|
DHR.PRA
937
DELISTED
Danaher Corporation 4.75% Mandatory Convertible Preferred Stock, Series A
DHR.PRA
| $43.2M | 0.01% |
39,210
| – | – |
|
938
Middleby
MIDD
$5.38B
| $43M | 0.01% |
316,584
-198,932
| -39% | -$26.7M |
|
|
GNMK
939
DELISTED
GenMark Diagnostics, Inc
GNMK
| $42.8M | 0.01% |
6,589,491
-1,101,642
| -14% | -$7.76M |
|
940
Saic
SAIC
$5.34B
| $42.7M | 0.01% |
493,744
-3,411
| -0.7% | -$268K |
|
|
CDR
941
DELISTED
Cedar Realty Trust, Inc
CDR
| $42.5M | 0.01% |
2,431,340
-16,337
| -0.7% | -$327K |
|
942
Ormat Technologies
ORA
$6.97B
| $42.3M | 0.01% |
667,565
-5,640
| -0.8% | -$336K |
|
943
Team
TISI
$101M
| $42.2M | 0.01% |
275,135
+860
| +0.3% | +$139K |
|
944
Murphy USA
MUSA
$10.1B
| $41.7M | 0.01% |
495,893
-4,074
| -0.8% | -$341K |
|
945
Cencora
COR
$60B
| $41.6M | 0.01% |
487,551
+200,638
| +70% | +$15.9M |
|
946
Celanese
CE
$4.75B
| $41.5M | 0.01% |
385,073
-12,920
| -3% | -$1.34M |
|
|
ANSS
947
DELISTED
Ansys
ANSS
| $41.3M | 0.01% |
201,630
+19
| +0% | +$3.62K |
|
|
FBMS
948
DELISTED
The First Bancshares, Inc.
FBMS
| $41.2M | 0.01% |
1,358,252
+80,962
| +6% | +$2.48M |
|
949
Parker-Hannifin
PH
$135B
| $41.1M | 0.01% |
241,814
-89
| -0% | -$15.3K |
|
950
Encompass Health
EHC
$12.3B
| $41.1M | 0.01% |
815,202
-2,987
| -0.4% | -$145K |
|
Similar funds
T. Rowe Price Associates's Q2 2019 Portfolio in Review
As of Q2 2019, T. Rowe Price Associates held 2,600 positions worth $712B, up 4.7% from $680B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
T. Rowe Price Associates's Q2 2019 filing shows 72 new, 1,394 increased, 949 reduced and 59 closed positions. Its largest new stake was Alcon: 36,020,796 shares worth $2.23B. The largest sale was UnitedHealth, an estimated $2.27B.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2019 buy was Alcon: 36,020,796 shares worth $2.23B.
- T. Rowe Price Associates added most to Linde in Q2 2019, an estimated $1.34B increase.
- T. Rowe Price Associates's biggest Q2 2019 reduction was UnitedHealth, cutting an estimated $2.27B.
- T. Rowe Price Associates fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $609M.
- T. Rowe Price Associates's ten largest holdings make up 21% of its $712B portfolio in Q2 2019.
- T. Rowe Price Associates opened 72 new positions and closed 59 in Q2 2019.
- T. Rowe Price Associates's portfolio value rose 4.7% quarter-over-quarter to $712B.
Based on T. Rowe Price Associates's 13F filing for Q2 2019, filed 15 Aug 2019.